Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET
Company Participants
Jessica Breu - Vice President, Investor Relations & Communications
Daniel Vitt - Chief Executive Officer, President & Director
Glenn Whaley - Chief Financial Officer
Conference Call Participants
Matt Kaplan - Ladenburg Thalmann
Jun-Goo Kwak - Piper Sandler
Mayank Mamtani - B. Riley
Tom Smith - Leerink Partners
Jessica Breu
Good morning, and welcome to Immunic First Quarter 2024 Earnings Call. My name is Jessica Breu, Vice President, Investor Relations and Communications here at Immunic. I will also be the moderator today.
Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer and President; as well as Glenn Whaley, our Chief Financial Officer. Please note that all participants will be in listen-only mode, and this event is being recorded. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]
Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate or words with a similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to differ materially from those discussed here.
Please note that these forward-looking statements reflect Immunic's opinions only as of the date of this presentation, and it undertakes no obligation to revise or publicly release the result of any revision to these forward-looking statements in light of new information or future events. Please refer to Immunic's SEC filings for a more detailed description of the risk factors that may affect Immunic's results and these forward-looking statements.
I would now like to turn the call over to our CEO and President, Dr. Daniel Vitt, to begin the presentation. Daniel?
Daniel Vitt
Yes. Thank you, Jessica. I would also like to welcome everybody on today's earnings call. Earlier this morning, we announced our financial results for the first quarter ended March 31, 2024, in our press release.
During the call today, we will walk through our first quarter 2024 achievements and subsequent highlights, financial and operating results as well as our clinical development programs, including anticipated upcoming milestones. As Jessica noted, after the presentation, you will have the opportunity to ask questions.
Let's start with a review of our first quarter 2024 and subsequent highlights. With our early January announcement of the completion of the three-tranche private placement of up to $240 million, we are well capitalized into the third quarter of 2024. This nicely covers the readout of our Phase 2 CALLIPER trial of our potentially groundbreaking lead assays vidofludimus calcium in progressive multiple sclerosis, which is anticipated in April 2025.